Louis Dubeau
Affiliations: | Biology | University of Southern California, Los Angeles, CA, United States |
Area:
General Biophysics, Molecular Biology, Neuroscience BiologyGoogle:
"Louis Dubeau"Mean distance: 13358.2
Children
Sign in to add traineeRajas Chodankar | grad student | 2004 | USC |
Sepideh Karimi | grad student | 2004 | USC |
Bongha Shin | grad student | 2004 | USC |
Jiamei Yu | grad student | 2004 | USC |
Youngjin Cho | grad student | 2006 | USC |
Hao Hong | grad student | 2008 | USC |
Vanessa Yu | grad student | 2009 | USC |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Haran S, Chindera K, Sabry M, et al. (2024) Natural Killer Cell Dysfunction in Premenopausal Mutation Carriers: A Potential Mechanism for Ovarian Carcinogenesis. Cancers. 16 |
Yuan B, Yang J, Dubeau L, et al. (2021) A Phosphotyrosine Switch in Estrogen Receptor β Is Required for Mouse Ovarian Function. Frontiers in Cell and Developmental Biology. 9: 649087 |
Dong S, Khedro T, Ward P, et al. (2020) First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia. British Journal of Haematology |
Widschwendter M, Dubeau L. (2020) Non-Surgical Cancer Risk Reduction in Mutation Carriers: Disabling the Remote Control. Cancers. 12 |
Samanta S, Tamura S, Dubeau L, et al. (2020) Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma. Scientific Reports. 10: 2160 |
Markland FS, Swenson S, Minea R, et al. (2019) Abstract C032: A novel integrin-targeted therapeutic agent for ovarian cancer Molecular Cancer Therapeutics |
Austria T, Marion C, Yu V, et al. (2018) Mechanism of cytokinesis failure in ovarian cystadenomas with defective brca1 and p53 pathways. International Journal of Cancer |
Barzi A, Campan M, Petterson J, et al. (2018) Assessment of microsatellite instability (MSI) in cell free DNA (cfDNA) of colorectal cancers (CRC) patients (pts). Journal of Clinical Oncology. 36: 672-672 |
Bacher J, Halberg R, Ward P, et al. (2018) Development of a pan-cancer biomarker panel for improved detection of MSI across all cancer types Annals of Oncology. 29: viii27-viii28 |
Samanta S, Tamura S, Dubeau L, et al. (2017) Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget. 8: 103543-103556 |